Sector News

GlaxoSmithKline bids adieu to vaccines president Luc Debruyne

June 13, 2018
Life sciences

GlaxoSmithKline has experienced multiple top executive departures under CEO Emma Walmsley, but the reformation of the company’s leadership isn’t finished yet. The company’s vaccines president Luc Debruyne will leave at the end of the year, the company said, to be replaced by Manufacturing & Supply President Roger Conner.

Luc Debruyne has served at GSK for 27 years, holding positions as general manager in the Netherlands, SVP of pharma in Europe and more.

He’s been president of GSK’s vaccines outfit for five years. During that time, the group has integrated Novartis’ vaccines assets, launched new shingles vaccine Shingrix and built up its presence in the U.S., according to the company.

With the company’s 2015 asset swap—orchestrated by former CEO Andrew Witty—GlaxoSmithKline doubled down in vaccines. A recent report from EvaluatePharma forecast the company will lead the vaccines industry in 2024 sales at $10.74 billion.

Last year, the company passed Merck to lead the industry’s sales rankings with a global vaccine haul of about $7.16 billion.

Vaccines have been a reliable growth contributor for GSK in recent years as the company’s pharma and consumer healthcare businesses have come under competitive pressures. Last year, vaccines sales grew by 6%, compared to 3% for pharma and 2% for consumer healthcare at constant exchange rates.

Conner will become president of GSK’s vaccines group on September 1. He has served on GSK’s corporate executive team since 2012 and led a transformation of the company’s supply chain, GSK said.

Starting in September, Regis Simard will take the role of pharmaceutical supply chain president. He is currently SVP of global pharma manufacturing.

Debruyne’s exit comes as Glaxo’s vaccines unit works to execute on its important Shingrix launch. The company won U.S. approval for the shingles vaccine last fall, and days later it picked up a preferential recommendation from the CDC.

GSK expects the vaccine to chip in $600 million in sales this year after it generated $150 million in the first quarter. It’s among a group of new approvals on a path to blockbuster sales, analysts predict.

Debruyne isn’t the only GSK executive to head for the exit in recent months and years. Last month, the company announced that longtime CFO Simon Dingemans is retiring next May. Since former CEO Witty left the company in March 2017, R&D chief Patrick Vallance has also exited, along with vaccines chairman Moncef Slaoui and Dominique Limet, head of HIV joint venture ViiV Healthcare.

As part of her strategy to reshape GSK’s executive team, Walmsley has looked to other global drug giants for experience. She hired former Roche executive Hal Barron as Glaxo’s R&D head and former AstraZeneca executive Luke Miels to run GSK’s pharma business.

GlaxoSmithKline is counting on Shingrix and two other newly approved drugs, HIV drug Juluca and respiratory drug Trelegy, to fuel growth as Advair continues its decline. Generics to Advair could hit the market this year, representing a revenue risk to Glaxo’s top drug.

Walmsley started as Glaxo’s CEO on March 31, 2017.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

November 26, 2023

ViCentra links insulin pump with Dexcom, Diabeloop tech to launch closed-loop diabetes system in Europe

Life sciences

Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.

November 26, 2023

Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech

Life sciences

Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.

November 26, 2023

EuroAPI completes acquisition of BianoGMP

Life sciences

EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.

How can we help you?

We're easy to reach